Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of
the Pharmaceutical Research and Manufacturers of America (PhRMA) today
at the trade association's annual meeting. Also elected were Kenneth C.
Frazier, chairman, president and CEO of Merck & Co, Inc., as
chairman-elect of the PhRMA Board of Directors, and George A. Scangos,
Ph.D., CEO of Biogen Idec, as Board treasurer.
Mr. Read succeeds Robert J. Hugin, chairman and CEO of Celgene
Corporation, as PhRMA's chairman.
"Bob Hugin is a true champion of the value that innovative medicines
deliver to patients, public health and our economy. Over the past year,
his tireless efforts to create new dialogues with partners in the
patient community and enthusiasm for better conveying the value of our
sector have greatly enhanced our advocacy for forward-looking policies
that promote innovation and provide patient access to new medicines,"
said PhRMA President and CEO John J. Castellani.
"At a time when collaborative medical science and healthcare delivery in
the U.S. and around the world are rapidly evolving, we are fortunate to
have Ian Read as chairman," Castellani added. "His vision for the future
of our healthcare system will help guide PhRMA as we embark on the many
challenges and opportunities ahead."
Mr. Read is the Chairman and CEO of Pfizer. He began his career with
Pfizer in 1978 as an operational auditor. Mr. Read worked in Latin
America through 1995, in roles including Chief Financial Officer, Pfizer
Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed
president of Pfizer's International Pharmaceuticals Group, with
responsibility for Latin America and Canada. He became Executive Vice
President, Europe, in 2000, and was named a Corporate Vice President in
2001, assuming responsibility for Canada, in addition to Europe, in
2002. Mr. Read later became accountable for operations in both the
Africa/Middle East region and Latin America. In 2006, he became senior
vice president, Pfizer, and Group President of the Worldwide
Biopharmaceutical Businesses, which he led through December 2010. In
that role, he oversaw five global business units - Primary Care,
Specialty Care, Oncology, Established Products and Emerging Markets.
"Our highest priority and purpose as an industry is to deliver
life-saving medicines to those who need them most. We are poised to
enter another golden era of innovation, transforming the way we do
research and development to speed the discovery of innovative new
medicines," Mr. Read said. "To be successful in our purpose, we must
have a reputation that ensures the full support of all segments of civil
society. We are judged, ultimately, by our actions and we must work hard
to earn the trust and respect of our regulators, legislators, healthcare
professionals, R&D partners and most importantly the patients who depend
on us, now and into te future."
Mr. Frazier is chairman and CEO of Merck & Co. Previously he served as
president of Merck with responsibility for the company's three major
divisions: Global Human Health, Merck's sales and marketing division for
pharmaceutical and vaccine products; Merck Manufacturing, the company's
manufacturing and supply division; and Merck Research Laboratories,
Merck's research organization. Mr. Frazier held a broad range of senior
management positions since joining Merck in 1992 as vice president,
general counsel and secretary of the Astra Merck Group. He received his
Bachelor's degree from Pennsylvania State University and holds a J.D.
from Harvard Law School.
"The outstanding contributions being made to society by the
biopharmaceutical companies who make up PhRMA's membership inspire me
every day. I am enthusiastic about my new responsibilities and look
forward to supporting PhRMA's ongoing efforts to advance healthcare for
patients, caregivers and society," Mr. Frazier said.
Dr. Scangos was appointed CEO of Biogen Idec in June 2010. He joined
Biogen Idec from Exelixis, Inc., where he served as president and CEO
since October 1996. From 1987 to 1996, Dr. Scangos held various
positions at Bayer, Inc., including SVP of R&D, and president of Bayer
Biotechnology, where he was responsible for research, business
development, process development, manufacturing, engineering and quality
assurance of Bayer's recombinant products. Before joining Bayer in 1987,
Dr. Scangos was Professor of Biology at Johns Hopkins University. Dr.
Scangos received a B.A. in Biology from Cornell University, and a Ph.D.
from the University of Massachusetts.
"We are entering an era of medical innovation that offers a real chance
to find therapies for some of the most challenging diseases, from
Alzheimer's, to ALS, to many of the cancers that now have few or no
treatments. Success will require not only superior science but also
sound public policy. I look forward to working with my industry
colleagues, policymakers, and others toward a world where patients can
reap the full promise of what our industry has to offer," said Dr.
The Pharmaceutical Research and Manufacturers of America (PhRMA)
represents the country's leading innovative biopharmaceutical research
and biotechnology companies, which are devoted to discovering and
developing medicines that enable patients to live longer, healthier, and
more productive lives. Since 2000, PhRMA member companies have invested
more than $550 billion in the search for new treatments and cures,
including an estimated $51.1 billion in 2013 alone.
Find PhRMA Online:
For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on ensuring the flow of medicines during public health
emergencies, visit http://www.rxresponse.org
[ Back To NFVZone's Homepage ]